WO2007128924A2 - Extrait aqueux de feuilles de tabac , ses utilisations dans le traitement de la dependance - Google Patents
Extrait aqueux de feuilles de tabac , ses utilisations dans le traitement de la dependance Download PDFInfo
- Publication number
- WO2007128924A2 WO2007128924A2 PCT/FR2007/000786 FR2007000786W WO2007128924A2 WO 2007128924 A2 WO2007128924 A2 WO 2007128924A2 FR 2007000786 W FR2007000786 W FR 2007000786W WO 2007128924 A2 WO2007128924 A2 WO 2007128924A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dependence
- treatment
- sterile water
- tobacco leaves
- tobacco
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Definitions
- the present invention relates to the use of a tobacco leaf extract for the preparation of a drug for the treatment of dependence.
- the invention also relates to a solution and a kit for injection comprising extracts of tobacco leaves.
- Dependence or addiction has been defined by the World Health Organization as "a syndrome in which the consumption of a product becomes a higher requirement than other behaviors that were previously of greater importance. In its extreme form the state of dependence is characterized by an irresistible need for a product that pushes the individual suffering from this dependence to impulsive research of this product. In France, it is estimated that there are about 200,000 individuals dependent on heroin and much less dependent on cocaine or derivatives of amphetamine. However, other products whose effects are less noticeable are addictive: alcohol, tobacco, coffee. This dependence also causes significant public health problems.
- Nicotine substitutes are therefore intended to provide the smoker's brain with a quantity of nicotine sufficient to avoid the symptoms of lack.
- Nicotine substitutes can be administered in a variety of ways, transdermally as patches or patches, orally as chewing gums, sucking tablets or sublingual tablets, or by air as an inhaler. Oral forms can be used alone or occasionally associated with the patch.
- the patches or patches deliver nicotine that is easily absorbed by the skin which helps to relieve the symptoms of physical withdrawal in relation to the lack of nicotine.
- Nicotine chewing gum provides oral nicotine that relieves symptoms of physical withdrawal.
- the number of chewing gums can be modified according to the level of pharmacological dependence, which is evaluated as for the patches by the responses to the Fagerstrôm test.
- the consumption of chewing gums usually lasts three months and it is recommended that they not be used more than six months after stopping smoking.
- Several therapeutic trials have shown that the effectiveness of these gums is comparable to that of patches, with a weaning rate of 19% at one year.
- the dose and the duration of the treatment must be sufficient and the mode of use must be respected (by sucking them at the beginning then by chewing them very slowly during 30 to 40 minutes). Indeed, if chewing is too fast, nicotine diffuses too quickly and may cause hyper salivation and sometimes gastric burns or hiccups. In addition, the gum is partly ineffective when swallowed because it is destroyed largely in the liver. Some ex-smokers also seem to have difficulty getting rid of the gums.
- the gums can be used in addition to the patch to calm a sudden craving for smoking, not covered by it. They are well suited to people who smoke irregularly and allow exfumers to play an active role in weaning. They also maintain a certain gesture. Nicotine can also be provided in the form of tablets to be deposited under the tongue or to suck.
- Nicotine can also be provided by inhalation.
- the inhaler consists of a mouthpiece with a cartridge that looks like a cigarette holder and delivers nicotine in the form of oral inhalations. If you want to smoke, the ex-smoker inhales a puff that gives him about 5 mg of nicotine.
- the inhaler not only relieves the symptoms of lack in relation to the absence of nicotine, but also act on the gesture by mimicking the act of smoking. It can, like chewing gums and sublingual or sucking tablets, be used in addition to a patch. Blood levels of nicotine are slower to obtain than when smoking a cigarette, so smokers must wait for their craving to quit.
- Another method of withdrawal is the administration of bupropion, marketed under the brand name
- Zyban® by GlaxoSmithKline Laboratories which acts on certain brain neuromediators such as catecholamines, norepinephrine and dopamine.
- ZYBAN® is a selective inhibitor of the neuronal reuptake of catecholamines, giving it antidepressant properties.
- This drug which has also been marketed in the United States since 1989 for its anti-depressive properties, makes it possible to reduce certain symptoms associated with weaning, such as the desire to smoke and the difficulties of concentration.
- Zyban® The efficacy of Zyban® is equivalent to that obtained after nicotine patches (weaning rate around 20%). Zyban® has also been shown in studies clinics good activity in chronic bronchitis, patients often heavy smokers who usually have trouble getting rid of tobacco.
- Zyban® acts on the psychic component of tobacco addiction and facilitates smoking cessation through a mechanism different from nicotine replacement therapy.
- Zyban® requires a doctor's prescription and may result in dry mouth, insomnia, and dizziness. This medicine has been the subject of pharmacovigilance surveillance measures by the French Health Products Safety Agency (Afssaps) because deaths have been observed in Great Britain after its administration. Nevertheless, serious reactions of this drug seem to be rare, when Zyban® has been correctly prescribed and its contraindications respected.
- the third way of weaning is homeopathy, which is based on the use in infinitesimal doses, obtained by successive dilutions, of the substance causing the symptoms that one wishes to combat. This is why an extract of "tabacum" is often used in smoking cessation.
- the Irish patent application IE 960 511 notably describes the use of homeopathic dilutions of tobacco extract for the manufacture of a medicament for the restoration of neuronal functions.
- addiction involves the participation of three neuromodulators, dopamine, norepinephrine and serotonin (Jean-Paul Tassin and Jacques Glowinski in Proceedings of the American Academy of Sciences, April 24, 2006) .
- the disruption of the production kinetics of these neuromodulators reflects the installation of the addiction.
- the present inventor has found that injection of an aqueous solution of an aqueous extract of tobacco leaves makes it possible to reduce the dependence. More particularly, the inventors have been able to demonstrate that a single injection of a tobacco extract according to the invention was generally sufficient to reduce or even eliminate the smoking dependence of smokers. This characteristic is a major benefit for the patient, as the products currently available on the market only provide long-term, multi-dose treatments.
- the treatment according to the invention proposes a shock therapy, that is to say a treatment consisting preferably of a single injection of a tobacco extract, optionally followed, after several days or weeks, of at least a second injection if the subject treated feels the need.
- the invention therefore relates to the use of an aqueous extract of tobacco leaves for the preparation of a drug for the treatment of dependence.
- the invention relates to the use of an aqueous extract of tobacco leaves for the preparation of a medicament in the form of a solution in sterile water for injection, preferably for administration by subcutaneous route, for the treatment of addiction.
- the aqueous extract of tobacco leaves comprises many compounds, but contains only very small amounts of nicotine, it can even be substantially free of nicotine.
- the inventor is of the opinion that the substances present in the aqueous extracts of tobacco leaves act against the pathological decoupling of the three main neuromodulators, namely dopamine, norepinephrine and serotonin.
- the present invention relates to the use of an aqueous extract of tobacco leaves for the preparation of a medicament for the treatment of tobacco addiction.
- the medicament is in the form of an injection for a single administration, preferably subcutaneously.
- tobacco leaf extracts has the effect of reducing durably (3 to 5 weeks) and very strongly or even completely the level of the requirements of the body thus inducing a suppression of the desire to take back the toxic substance whose patient is dependent, especially the cigarette, and associated stresses.
- a single injection is usually sufficient to reduce or suppress the symptoms of smoking addiction.
- at least one further subsequent injection may be required depending on the patient being treated, particularly depending on his level of smoking dependence.
- the skilled person is able to adapt the time interval between the first and the second injection depending on each patient, and possibly the additional number of injections.
- the tolerance is perfect, without the risk of developing any addiction.
- the invention relates to the use of an aqueous extract of tobacco leaves with a solids content, expressed in mg / ml, of 0.05 to 150 mg of dry matter per ml of sterile water, preferably from 0.5 to 100 mg per ml of sterile water, and more preferably from 1 to 20 mg per ml of sterile water, for the preparation of a solution for injection for the treatment of dependence.
- aqueous extracts of tobacco leaves are not toxic, especially when administered subcutaneously.
- the invention therefore relates to the use of an aqueous extract of tobacco leaves for the preparation of a single injection for the treatment of dependence.
- the invention therefore also relates to the use of an aqueous extract of tobacco leaves for the preparation of at least two injections made at time intervals of 4 to 30, preferably 5 to 15, more preferably still from 6 to 13 days.
- the need for a second injection, and possibly other additional injections, will be determined for each patient based on the results obtained after the first injection and / or following previous injections.
- the number of injections should not be greater than 5, preferably not more than 4, and more preferably not more than 2.
- the invention also relates to sterile aqueous solutions of aqueous extracts of tobacco leaves with a solids content of from 0.05 to 150 mg / ml, preferably from 0.5 to 100 mg / ml, and more preferably from 1 to at 20 mg / ml sterile water.
- the aqueous extracts are lyophilized.
- the invention also relates to aqueous sterile solutions of an aqueous extract of tobacco leaves with a solids content of 0.05 to 50 mg / ml of sterile water, preferably 0, 5 to 20 mg / ml of sterile water, and more preferably still 1 to 15 mg / ml of sterile water, preferably said extract being lyophilized.
- the invention also relates to a ready-to-use kit comprising a syringe, a vial filled with sterile water and an aqueous extract lyophilisate of tobacco leaves.
- aqueous solutions and this kit are intended to be used in the treatment of dependence, more particularly of tobacco addiction.
- Each of the 150 patients then received a subcutaneous injection (in the forearm or buttock) of a solution prepared above.
- the treatment is short-lived and much less expensive than the current multi-month treatments.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Manufacture Of Tobacco Products (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2008014247A MX2008014247A (es) | 2006-05-09 | 2007-05-09 | Extracto acuoso de hojas de tabaco, usos del mismo en el tratamiento de dependencia. |
US12/299,850 US9061052B2 (en) | 2006-05-09 | 2007-05-09 | Aqueous extract of tobacco leaves, its uses in the treatment of dependence |
CA2651296A CA2651296C (fr) | 2006-05-09 | 2007-05-09 | Extrait aqueux de feuilles de tabac, ses utilisations dans le traitement de la dependance |
UAA200814049A UA94461C2 (ru) | 2006-05-09 | 2007-05-09 | Водный экстракт листьев табака и его применение для лечения состояния зависимости |
EP07731427.6A EP2015764B1 (fr) | 2006-05-09 | 2007-05-09 | Extrait aqueux de feuilles de tabac , ses utilisations dans le traitement de la dependance |
JP2009508426A JP5253383B2 (ja) | 2006-05-09 | 2007-05-09 | 依存症の治療におけるタバコ葉の水性抽出物とそれの使用 |
BRPI0711363-3A BRPI0711363A2 (pt) | 2006-05-09 | 2007-05-09 | extrato aquoso de folhas de tabaco, as respectivas utilizações no tratamento da dependência |
KR1020087027534A KR101416944B1 (ko) | 2006-05-09 | 2007-05-09 | 담배잎의 수성 추출물, 의존성 치료에 있어서의 그의 용도 |
ES07731427.6T ES2562430T3 (es) | 2006-05-09 | 2007-05-09 | Extracto acuoso de hojas de tabaco, sus utilizaciones en el tratamiento de la dependencia |
IL195096A IL195096A (en) | 2006-05-09 | 2008-11-04 | Use of aqueous solution of tobacco leaf extract to manufacture a drug for the treatment of tobacco dependence and kits containing it |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0604104A FR2900825B1 (fr) | 2006-05-09 | 2006-05-09 | Extrait aqueux de feuilles de tabac, ses utilisations dans le traitement de la dependance |
FR0604104 | 2006-05-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007128924A2 true WO2007128924A2 (fr) | 2007-11-15 |
WO2007128924A3 WO2007128924A3 (fr) | 2008-04-17 |
Family
ID=37547454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2007/000786 WO2007128924A2 (fr) | 2006-05-09 | 2007-05-09 | Extrait aqueux de feuilles de tabac , ses utilisations dans le traitement de la dependance |
Country Status (14)
Country | Link |
---|---|
US (1) | US9061052B2 (fr) |
EP (1) | EP2015764B1 (fr) |
JP (1) | JP5253383B2 (fr) |
KR (1) | KR101416944B1 (fr) |
CN (2) | CN104758445A (fr) |
BR (1) | BRPI0711363A2 (fr) |
CA (1) | CA2651296C (fr) |
ES (1) | ES2562430T3 (fr) |
FR (1) | FR2900825B1 (fr) |
IL (1) | IL195096A (fr) |
MX (1) | MX2008014247A (fr) |
RU (1) | RU2445971C2 (fr) |
UA (1) | UA94461C2 (fr) |
WO (1) | WO2007128924A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017174787A1 (fr) * | 2016-04-07 | 2017-10-12 | Nfl Biosciences | Extrait de feuilles de tabac et utilisation pour le traitement de l'addiction au tabac |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE202014103194U1 (de) * | 2014-07-11 | 2014-07-29 | Marianna Gross | Homöopathisches Mittel zur Raucherentwöhnung |
CN104997929A (zh) * | 2015-07-09 | 2015-10-28 | 淮海工学院 | 一种戒烟外用软膏 |
KR102245907B1 (ko) * | 2019-06-07 | 2021-04-29 | 한국화학연구원 | 맥문동(Liriope platyphylla) 추출물을 유효성분으로 함유하는 니코틴 중독 의 예방 또는 치료용 조성물 |
WO2024089465A2 (fr) * | 2022-10-24 | 2024-05-02 | Nfl Biosciences | Procédés de traitement impliquant des extraits de feuilles de tabac pour aider au sevrage tabagique |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE960511A1 (en) * | 1996-07-15 | 1998-01-28 | Michael Anthony Folan | Nicotine-containing homeopathic dilution and its use in¹restoring neuronal function |
EP1304048A1 (fr) * | 2001-10-22 | 2003-04-23 | Ivo Pera | Composition pour réduire ou arrêter le tabagisme |
US20030185908A1 (en) * | 1998-06-05 | 2003-10-02 | Regent Court Technologies | Monoamine oxidase (MAO) inhibitors and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6468326A (en) | 1987-09-09 | 1989-03-14 | Tsuguhiro Kawamoto | Remedy for athlete's foot |
JP3284042B2 (ja) | 1996-03-19 | 2002-05-20 | 臣平 松田 | 歯周病の予防用或いは治療用組成物 |
RU2147242C1 (ru) * | 1999-08-24 | 2000-04-10 | Добротин Виктор Евгеньевич | Средство для лечения табакокурения |
-
2006
- 2006-05-09 FR FR0604104A patent/FR2900825B1/fr active Active
-
2007
- 2007-05-09 CA CA2651296A patent/CA2651296C/fr active Active
- 2007-05-09 EP EP07731427.6A patent/EP2015764B1/fr active Active
- 2007-05-09 JP JP2009508426A patent/JP5253383B2/ja active Active
- 2007-05-09 US US12/299,850 patent/US9061052B2/en active Active
- 2007-05-09 MX MX2008014247A patent/MX2008014247A/es active IP Right Grant
- 2007-05-09 BR BRPI0711363-3A patent/BRPI0711363A2/pt not_active Application Discontinuation
- 2007-05-09 ES ES07731427.6T patent/ES2562430T3/es active Active
- 2007-05-09 CN CN201510116717.7A patent/CN104758445A/zh active Pending
- 2007-05-09 KR KR1020087027534A patent/KR101416944B1/ko active IP Right Grant
- 2007-05-09 CN CNA2007800164993A patent/CN101437530A/zh active Pending
- 2007-05-09 UA UAA200814049A patent/UA94461C2/ru unknown
- 2007-05-09 RU RU2008148334/15A patent/RU2445971C2/ru active
- 2007-05-09 WO PCT/FR2007/000786 patent/WO2007128924A2/fr active Application Filing
-
2008
- 2008-11-04 IL IL195096A patent/IL195096A/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE960511A1 (en) * | 1996-07-15 | 1998-01-28 | Michael Anthony Folan | Nicotine-containing homeopathic dilution and its use in¹restoring neuronal function |
US20030185908A1 (en) * | 1998-06-05 | 2003-10-02 | Regent Court Technologies | Monoamine oxidase (MAO) inhibitors and uses thereof |
EP1304048A1 (fr) * | 2001-10-22 | 2003-04-23 | Ivo Pera | Composition pour réduire ou arrêter le tabagisme |
Non-Patent Citations (1)
Title |
---|
ANTHENELLI ET AL: "Recent advances in the treatment of tobacco dependence" CLINICAL NEUROSCIENCE RESEARCH, ELSEVIER, LONDON, GB, vol. 5, no. 2-4, novembre 2005 (2005-11), pages 175-183, XP005149967 ISSN: 1566-2772 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017174787A1 (fr) * | 2016-04-07 | 2017-10-12 | Nfl Biosciences | Extrait de feuilles de tabac et utilisation pour le traitement de l'addiction au tabac |
FR3049866A1 (fr) * | 2016-04-07 | 2017-10-13 | Nfl Biosciences | Extrait de feuilles de tabac et utilisation pour le traitement de l'addiction au tabac |
US11123395B2 (en) | 2016-04-07 | 2021-09-21 | Nfl Biosciences | Protein containing tobacco leaf extracts |
AU2017248103B2 (en) * | 2016-04-07 | 2023-12-14 | Nfl Biosciences | Tobacco leaf extract and use thereof for the treatment of tobacco addiction |
US11865156B2 (en) | 2016-04-07 | 2024-01-09 | Nfl Biosciences | Treatment of tobacco addiction by a tobacco leaf extract |
EP4285999A3 (fr) * | 2016-04-07 | 2024-03-13 | NFL Biosciences | Extrait de feuilles de tabac et utilisation pour le traitement de l'addiction au tabac |
Also Published As
Publication number | Publication date |
---|---|
WO2007128924A3 (fr) | 2008-04-17 |
CA2651296A1 (fr) | 2007-11-15 |
IL195096A0 (en) | 2009-08-03 |
MX2008014247A (es) | 2009-04-30 |
RU2445971C2 (ru) | 2012-03-27 |
JP5253383B2 (ja) | 2013-07-31 |
CN104758445A (zh) | 2015-07-08 |
KR20090014348A (ko) | 2009-02-10 |
CN101437530A (zh) | 2009-05-20 |
UA94461C2 (ru) | 2011-05-10 |
ES2562430T3 (es) | 2016-03-04 |
JP2009536183A (ja) | 2009-10-08 |
EP2015764A2 (fr) | 2009-01-21 |
US9061052B2 (en) | 2015-06-23 |
FR2900825B1 (fr) | 2012-10-26 |
CA2651296C (fr) | 2016-08-16 |
RU2008148334A (ru) | 2010-06-20 |
KR101416944B1 (ko) | 2014-07-08 |
EP2015764B1 (fr) | 2015-11-18 |
BRPI0711363A2 (pt) | 2011-11-22 |
US20090142426A1 (en) | 2009-06-04 |
IL195096A (en) | 2015-11-30 |
FR2900825A1 (fr) | 2007-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6893654B2 (en) | Two-stage transmucosal medicine delivery system for symptom relief | |
Malhotra et al. | Nicotine and periodontal tissues | |
Jiloha | Pharmacotherapy of smoking cessation | |
Gourlay et al. | Antismoking products | |
HUT74920A (en) | Improved nicotine lozenge and therapeutic method for smoking cessation | |
CH702775B1 (fr) | Pastilles de gélatine douces contenant de la nicotine et procédé de préparation. | |
BRPI0810525B1 (pt) | Uso de pioglitazona ou rosiglitazona pra tratar a dependência em álcool, cocaína e nicotina, composições farmacêuticas e formas de dosagem, e combinações farmacêuticas contendo pioglitazona ou rosiglitazona | |
EP2015764B1 (fr) | Extrait aqueux de feuilles de tabac , ses utilisations dans le traitement de la dependance | |
FR2460670A1 (fr) | Composition pour aider les fumeurs a arreter de fumer, la composition contenant un derive de la 2-imidazoline et un anorexique | |
RU2262352C2 (ru) | Применение агонистов рецепторов b-типа гамма-аминомасляной кислоты и их фармацевтически приемлемых производных при лечении никотиновой зависимости | |
US20050100513A1 (en) | Homeopathic method and system for treating nicotine addiction | |
Rose | Disrupting nicotine reinforcement: from cigarette to brain | |
JP2009536183A5 (fr) | ||
KR20120106671A (ko) | 혈중 화학 물질을 제거하기 위한 방법 및 투약 요법 | |
Prignot | Pharmacological approach to smoking cessation | |
US6630449B2 (en) | Method for reducing the effect of nicotine addiction and dependancy | |
RU2745039C1 (ru) | Никотинсодержащая съедобная бумага | |
US20020168403A1 (en) | Compositions and therapy for substance addiction | |
Jiménez-Ruiz et al. | Pharmacological Tobacco Cessation Treatments: Proposals for Financing | |
Miller et al. | Nicotine dependence: diagnosis, chemistry and pharmacological treatments | |
Kumar et al. | Nicotine addiction and its Pharmacological effects: A Review | |
RU2235542C1 (ru) | Способ лечения табакокурения | |
Roopchandani et al. | Smoking cessation aids | |
HENNINGFIELD | AUGUST R. BUCHHALTER, REGINALD V. FANT | |
EA012460B1 (ru) | Лекарство и способ для снижения потребления алкоголя и/или табака |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07731427 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007731427 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2651296 Country of ref document: CA Ref document number: 12008502441 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12299850 Country of ref document: US Ref document number: MX/A/2008/014247 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009508426 Country of ref document: JP Ref document number: 200780016499.3 Country of ref document: CN Ref document number: 6080/CHENP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087027534 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008148334 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0711363 Country of ref document: BR Kind code of ref document: A2 Effective date: 20081107 |